GFAP and Parkinson disease: These proteins were chosen because blood GFAP is an FDA authorized marker in individuals with suspected TBI [23] and both the proteins have distinguished roles in synaptic plasticity and neurogenesis, with reported associations in Parkinson’s and dementia [24–29].